At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
UNCY Unicycive Therapeutics, Inc.
Market Closed 12-12 16:00:00 EST
6.23
-0.18
-2.81%
盘后6.32
+0.09+1.44%
18:47 EST
High6.57Low6.20Vol249.80K
Open6.41D1 Closing6.41Amplitude5.85%
Mkt Cap133.89MTradable Cap81.04MTotal Shares21.49M
T/O1.58MT/O Rate1.92%Tradable Shares13.01M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation
Reuters  ·  12-03
Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
GlobeNewswire  ·  11-25
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning
TIPRANKS  ·  11-16
Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning
Unicycive Therapeutics Doubles Stock Sale Agreement
TIPRANKS  ·  11-15
Unicycive Therapeutics Doubles Stock Sale Agreement
BRIEF-Unicycive Therapeutics Increases ATM Offering To $100 Million - SEC Filing
Reuters  ·  11-15
BRIEF-Unicycive Therapeutics Increases ATM Offering To $100 Million - SEC Filing
Unicycive Therapeutics Inc - Increases Atm Offering to $100 Mln - SEC Filing
THOMSON REUTERS  ·  11-15
Unicycive Therapeutics Inc - Increases Atm Offering to $100 Mln - SEC Filing
Unicycive Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate, Cash And Cash Equivalents Totaled $42.7M, With Cash Runway Into 2027
Benzinga  ·  11-12
Unicycive Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate, Cash And Cash Equivalents Totaled $42.7M, With Cash Runway Into 2027
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Strategy
Reuters  ·  11-12
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Strategy
Unicycive Therapeutics reports Q3 results with $42.7 million cash and plans OLC NDA resubmission by year-end
Reuters  ·  11-12
Unicycive Therapeutics reports Q3 results with $42.7 million cash and plans OLC NDA resubmission by year-end
Unicycive Therapeutics Inc - on Track to Resubmit Nda for Oxylanthanum Carbonate by Year-End
THOMSON REUTERS  ·  11-12
Unicycive Therapeutics Inc - on Track to Resubmit Nda for Oxylanthanum Carbonate by Year-End
Unicycive Therapeutics Reports Oxylanthanum Carbonate Cuts Pill Burden in Hyperphosphatemia Trial
Reuters  ·  10-30
Unicycive Therapeutics Reports Oxylanthanum Carbonate Cuts Pill Burden in Hyperphosphatemia Trial
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), United Therapeutics (UTHR) and Unicycive Therapeutics (UNCY)
TIPRANKS  ·  10-30
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), United Therapeutics (UTHR) and Unicycive Therapeutics (UNCY)
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Development Plans
Reuters  ·  10-30
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Development Plans
Guggenheim Sticks to Its Buy Rating for Unicycive Therapeutics (UNCY)
TIPRANKS  ·  10-30
Guggenheim Sticks to Its Buy Rating for Unicycive Therapeutics (UNCY)
Unicycive Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  10-29
Unicycive Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Unicycive Therapeutics Inc : H.c. Wainwright Raises Target Price to $22 From $9
THOMSON REUTERS  ·  10-29
Unicycive Therapeutics Inc : H.c. Wainwright Raises Target Price to $22 From $9
Unicycive Therapeutics to Resubmit OLC NDA After FDA Meeting
Reuters  ·  10-28
Unicycive Therapeutics to Resubmit OLC NDA After FDA Meeting
Unicycive Therapeutics Provides Update From FDA Type a Meeting and Expects to Resubmit Olc Nda Before Year-End
THOMSON REUTERS  ·  10-28
Unicycive Therapeutics Provides Update From FDA Type a Meeting and Expects to Resubmit Olc Nda Before Year-End
Class Action Lawsuit Filed Against Unicycive Therapeutics Inc for Alleged Securities Fraud
Reuters  ·  10-10
Class Action Lawsuit Filed Against Unicycive Therapeutics Inc for Alleged Securities Fraud
Unicycive Therapeutics Faces Class Action Lawsuit Alleging Securities Fraud; Investors Urged to Take Action
Reuters  ·  10-04
Unicycive Therapeutics Faces Class Action Lawsuit Alleging Securities Fraud; Investors Urged to Take Action

Introduction

Company Name.
Unicycive Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Issue price:
--